恶性胸膜间皮瘤治疗中的肿瘤学前沿
Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma.
作者信息
Vita Emanuele, Stefani Alessio, Di Salvatore Mariantonietta, Chiappetta Marco, Lococo Filippo, Margaritora Stefano, Tortora Giampaolo, Bria Emilio
机构信息
Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy.
Medical Oncology, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.
出版信息
J Clin Med. 2021 May 25;10(11):2290. doi: 10.3390/jcm10112290.
Abstract
Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by very poor prognosis and lack of treatment options. Immunotherapy has rapidly emerged as an effective tool for MPM, particularly for tumors of non-epithelioid histology. At the same time, comprehensive genomic sequencing may open the way to new-generation targeted-drugs able to hit specific MPM molecular vulnerabilities. These innovations will possibly enrich, but also dramatically complicate, the elucidation of treatment algorithms. Multidisciplinary integration is urgently needed.
摘要
恶性胸膜间皮瘤（MPM）是一种罕见的恶性肿瘤，其特点是预后极差且缺乏治疗选择。免疫疗法已迅速成为治疗MPM的有效手段，尤其是对于非上皮样组织学类型的肿瘤。与此同时，全面的基因组测序可能为能够针对MPM特定分子弱点的新一代靶向药物开辟道路。这些创新可能会丰富治疗算法的阐释，但也会使其显著复杂化。迫切需要多学科整合。
相似文献
1
Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤治疗中的肿瘤学前沿
J Clin Med. 2021 May 25;10(11):2290. doi: 10.3390/jcm10112290.
2
Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma.蛋白骨桥蛋白在恶性胸膜间皮瘤进展中的重要功能作用。
Front Immunol. 2023 Jun 16;14:1116430. doi: 10.3389/fimmu.2023.1116430. eCollection 2023.
3
New therapeutic strategies for malignant pleural mesothelioma.恶性胸膜间皮瘤的新治疗策略
Biochem Pharmacol. 2017 Jan 1;123:8-18. doi: 10.1016/j.bcp.2016.07.012. Epub 2016 Jul 16.
4
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma.生物标志物引导的恶性胸膜间皮瘤靶向治疗与免疫治疗
Ther Adv Med Oncol. 2020 Nov 12;12:1758835920971421. doi: 10.1177/1758835920971421. eCollection 2020.
5
Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.2013-2017 年英国恶性胸膜间皮瘤患者的治疗模式和结局：来自 I-O Optimise 计划的全国性 CAS 注册分析。
Lung Cancer. 2021 Dec;162:185-193. doi: 10.1016/j.lungcan.2021.11.001. Epub 2021 Nov 10.
6
Repurposing therapeutics for malignant pleural mesothelioma (MPM) - Updates on clinical translations and future outlook.将治疗药物重新用于恶性胸膜间皮瘤（MPM）-临床转化的最新进展和未来展望。
Life Sci. 2022 Sep 1;304:120716. doi: 10.1016/j.lfs.2022.120716. Epub 2022 Jun 13.
7
Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.恶性胸膜间皮瘤和间皮增生：一种用于鉴别诊断的新分子工具。
Oncotarget. 2017 Jan 10;8(2):2758-2770. doi: 10.18632/oncotarget.13174.
8
Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy.空间分辨的高维转录组学解析双相恶性胸膜间皮瘤的演变：免疫治疗的新范例。
Mol Cancer. 2023 Jul 17;22(1):114. doi: 10.1186/s12943-023-01816-9.
9
Malignant pleural mesothelioma: an update on diagnosis and treatment options.恶性胸膜间皮瘤：诊断与治疗选择的最新进展
Ther Adv Respir Dis. 2016 Jun;10(3):275-88. doi: 10.1177/1753465816628800. Epub 2016 Feb 12.
10
What's the place of immunotherapy in malignant mesothelioma treatments?免疫疗法在恶性间皮瘤治疗中的地位如何？
Cell Adh Migr. 2010 Jan-Mar;4(1):153-61. doi: 10.4161/cam.4.1.11361. Epub 2010 Jan 30.
引用本文的文献
1
The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical/surgical care: a narrative review.恶性胸膜间皮瘤发生中的遗传易感性：体细胞和种系变异、临床病理特征及其在实际医学/外科治疗中的意义：一项叙述性综述
J Thorac Dis. 2024 Jan 30;16(1):671-687. doi: 10.21037/jtd-23-611. Epub 2024 Jan 10.
2
Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma.人类 γδ T 细胞介导的杀伤恶性胸膜间皮瘤的三种不同机制。
Front Immunol. 2023 Mar 17;14:1058838. doi: 10.3389/fimmu.2023.1058838. eCollection 2023.
3
Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma.尼伏鲁单抗联合伊匹单抗作为不可切除恶性胸膜间皮瘤美国患者一线治疗的成本效益。
Front Public Health. 2022 Jul 22;10:947375. doi: 10.3389/fpubh.2022.947375. eCollection 2022.
4
Improved Survival and Quality of Life Through an Integrative, Multidisciplinary Oncological Approach: Pathophysiological Analysis of Four Clinical Cancer Cases and Review of the Literature.通过综合、多学科肿瘤学方法提高生存率和生活质量：四例临床癌症病例的病理生理分析及文献综述
Front Pharmacol. 2022 Jun 16;13:867907. doi: 10.3389/fphar.2022.867907. eCollection 2022.
5
Hyperthermic Intrathoracic Chemotherapy for Malignant Pleural Mesothelioma: The Forefront of Surgery-Based Multimodality Treatment.恶性胸膜间皮瘤的热胸内化疗：基于手术的多模式治疗前沿
J Clin Med. 2021 Aug 25;10(17):3801. doi: 10.3390/jcm10173801.
6
Effect of Asbestos Consumption on Malignant Pleural Mesothelioma in Italy: Forecasts of Mortality up to 2040.意大利石棉消费对恶性胸膜间皮瘤的影响：至2040年的死亡率预测
Cancers (Basel). 2021 Jul 3;13(13):3338. doi: 10.3390/cancers13133338.
本文引用的文献
1
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.纳武利尤单抗对比安慰剂治疗复发恶性间皮瘤患者（CONFIRM）：一项多中心、双盲、随机、III 期临床试验。
Lancet Oncol. 2021 Nov;22(11):1530-1540. doi: 10.1016/S1470-2045(21)00471-X. Epub 2021 Oct 14.
2
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.帕博利珠单抗在开放标签、单臂2期KEYNOTE-158研究中治疗晚期间皮瘤患者的疗效和安全性。
Lancet Respir Med. 2021 Jun;9(6):613-621. doi: 10.1016/S2213-2600(20)30515-4. Epub 2021 Apr 6.
3
Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification.恶性胸膜间皮瘤的综合转录组分析揭示了一种具有临床相关性的基于免疫的分类。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001601.
4
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.鲁卡帕尼用于BAP1缺陷或BRCA1缺陷的间皮瘤患者（MiST1）：一项开放标签、单臂、2a期临床试验。
Lancet Respir Med. 2021 Jun;9(6):593-600. doi: 10.1016/S2213-2600(20)30390-8. Epub 2021 Jan 27.
5
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.一线纳武利尤单抗联合伊匹单抗治疗不可切除恶性胸膜间皮瘤（CheckMate 743）：一项多中心、随机、开放标签、III 期临床试验。
Lancet. 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. Epub 2021 Jan 21.
6
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
7
Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study.II期RAMES研究中恶性胸膜间皮瘤（MPM）的突变谱
Cancers (Basel). 2020 Oct 13;12(10):2948. doi: 10.3390/cancers12102948.
8
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.一项比较派姆单抗与单药化疗治疗晚期预处理恶性胸膜间皮瘤的多中心随机 III 期试验：欧洲胸部肿瘤平台（ETOP 9-15）PROMISE-meso 试验。
Ann Oncol. 2020 Dec;31(12):1734-1745. doi: 10.1016/j.annonc.2020.09.009. Epub 2020 Sep 22.
9
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.一项关于尼拉帕利联合多斯塔利单抗治疗晚期非小细胞肺癌和/或恶性胸膜间皮瘤患者的前瞻性II期单臂研究，这些患者的PD-L1表达呈阳性且DNA修复基因存在种系或体细胞突变：理论依据和研究设计
Clin Lung Cancer. 2021 Jan;22(1):e63-e66. doi: 10.1016/j.cllc.2020.07.014. Epub 2020 Aug 5.
10
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.度伐利尤单抗联合一线化疗用于未经治疗的恶性胸膜间皮瘤（DREAM）：一项多中心、单臂、Ⅱ期、有安全爬坡阶段的研究
Lancet Oncol. 2020 Sep;21(9):1213-1223. doi: 10.1016/S1470-2045(20)30462-9.
Zotero 插件